Welcome to our dedicated page for Amphastar Pharma news (Ticker: AMPH), a resource for investors and traders seeking the latest updates and insights on Amphastar Pharma stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company focused on technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products. The AMPH news feed on Stock Titan brings together the company’s press releases and market-moving updates so readers can follow how its product portfolio, licensing deals, and financial performance evolve over time.
News about Amphastar often centers on regulatory milestones and pipeline progress. The company has reported U.S. Food and Drug Administration approval of its ANDA for Iron Sucrose Injection, USP, a generic iron sucrose injection indicated for iron deficiency anemia in chronic kidney disease. It also issues updates on its ANDAs, biosimilar insulin candidate, and proprietary peptide and protein products, including licensed peptide assets targeting oncology and ophthalmology.
Another recurring theme in AMPH news is strategic licensing and research agreements. Amphastar has announced exclusive license agreements with Nanjing Anji Biotechnology Co., Ltd. and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for proprietary peptide products and for AMP-110, a fully synthetic ACTH analog in early-phase human clinical development. The company also discloses contract research agreements for recombinant peptide research cell banks supporting its pipeline.
Investors can also track quarterly earnings releases, non-GAAP financial metrics, and share repurchase authorizations, as well as announcements about expanded manufacturing capacity and distribution partnerships, such as the exclusive distribution of BAQSIMI® in parts of the Greater China region. By following AMPH news, readers gain insight into Amphastar’s mix of complex generics, proprietary medicines, manufacturing footprint, and related-party agreements that shape its long-term business profile.
Amphastar Pharmaceuticals announced that the FDA has tentatively approved its ANDA for Vasopressin injection, a critical drug indicated for increasing blood pressure in adults with vasodilatory shock. The market for VASOSTRICT®, the branded equivalent, was approximately $856 million in U.S. sales as of September 30, 2021. Amphastar plans to manufacture its product in the U.S. The company has several additional products in its pipeline, targeting a combined market size of over $28 billion.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) participated in the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021. Key executives, including CFO Bill Peters and V.P. of Corporate Communications Dan Dischner, engaged in an analyst-moderated fireside chat. The presentation will be available on Amphastar's website starting the same day at 10:00 AM EST and will remain accessible for 90 days. Amphastar focuses on developing and marketing injectable and inhalation products used in clinical settings. For more details, visit ir.amphastar.com.
Amphastar Pharmaceuticals (NASDAQ:AMPH) announced participation in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on November 18, 2021. Key executives, including Bill Peters and Dan Dischner, will present a pre-recorded session available at 8:00 am GMT. The event will be accessible for 90 days via the company's website. Amphastar specializes in developing and manufacturing generic and proprietary injectable and inhalation products, primarily for hospital and urgent care settings.
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported a strong financial performance for Q3 2021, with net revenues reaching $112.2 million, up 34% from $83.4 million in Q3 2020. The GAAP net income was $29.5 million, or $0.59 per share. Key product drivers included Primatene Mist, epinephrine, and glucagon, showing substantial sales increases. The company also highlighted a robust pipeline with several products aimed at a combined market size exceeding $27 billion. The significant gain from the restructuring of its Chinese subsidiary contributed to non-operating income growth.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will announce its third-quarter 2021 results on November 8, 2021, after market close. The company will host a conference call at 2:00 p.m. PT to discuss the financial outcomes. Amphastar specializes in developing and marketing generic and proprietary injectable, inhalation, and intranasal products, primarily for hospital use. The call can be accessed via telephone or through the company’s investor website.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 9, 2021, at 2:00 PM ET. Key executives including CFO Bill Peters and Sr. VP Tony Marrs will participate in the presentation. A webcast will be available for viewing on Amphastar's website for 90 days post-event. Amphastar specializes in developing and marketing generic and proprietary injectable, inhalation, and intranasal products, primarily for clinical settings.
Amphastar Pharmaceuticals reported net revenues of $101.7 million for Q2 2021, an 18% increase from the previous year. The company achieved a GAAP net income of $7.8 million ($0.16 per share) and an adjusted non-GAAP net income of $10.6 million ($0.21 per share). Key growth drivers included strong sales of Primatene Mist, glucagon, and epinephrine. The company also announced plans to increase its share buyback program by $20 million and refinanced $30 million of debt, enhancing financial flexibility.
Amphastar Pharmaceuticals (NASDAQ:AMPH) will announce its second quarter 2021 results on August 9, 2021, after market close. A conference call is scheduled for 2:00 PM Pacific Time to discuss these results. The company specializes in developing, manufacturing, and marketing generic and proprietary injectable and inhalation products mainly used in clinical settings. The conference call can be accessed by dialing (877) 407-0989 for domestic calls or (201) 389-0921 for international calls.
Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that key executives will present at the Human Health Innovation Conference on June 22, 2021, at 2:00 PM Eastern Time. The panel includes Bill Peters (CFO), Dan Dischner (VP of Corporate Communications), Tony Marrs (SVP of Regulatory Affairs), and Jacob Liawatidewi (EVP of Corporate Administration). A webcast of the presentation will be accessible on Amphastar's website for 90 days following the event. Amphastar focuses on developing and marketing challenging generic and proprietary injectable products.
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) will participate in an Analyst-Moderated fireside chat at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2:30 pm Eastern Time. Key executives, including CFO Bill Peters and VP Dan Dischner, will be present. The event will be webcast and available for 90 days on Amphastar's website. Amphastar specializes in developing and marketing technically challenging generic and proprietary injectable, inhalation, and intranasal products, primarily for hospital use.